This trial let us know that tirzepatide had the capacity to help patients without diabetes lose an average of about 20% of their body weight when taking the 15 mg dose
Deng F, Zhang P, Li H, Fan X, Du Y, Zhong X, et al
1 On the on-treatment figure, CagriSema produced an average weight loss of 22.7%, compared with 16.1% for semaglutide, 11.8% for cagrilintide, and 2.3% for placebo
The patient initially presented with ataxia, left-sided weakness, and hemihypesthesia
But this is exactly what you need to focus on first
From dose calculators to storage guides to complete administration protocols, everything is designed to make peptide use as safe and effective as possible